Frequency Therapeutics — Hearing Loss Regeneration

If they could show positive results with FX-322, that would be great.

This year is my 20 anniversary of my first sudden hearing loss in 2003. Inbetween I really always took care of my ears but sometimes I ran in some situations where I was hit by some unforeseen loud events. Or maybe I was in noisy environments. Or my ears behaved strange because of overprotection during all these years.

There were always some episodes where I could forget my tinnitus and hearing loss, but there are also always repeating situations of discomfort and fear with my hearing conditions.

Anyway, it would be very valuable if Frequency Therapeutics could enhance hearing experience in some way. All other findings in labs or universities are very far away from practical use. Maybe Frequency Therapeutics could optimize its compound further and further.

We will see. I really pray hard that there is further development of FX-322 and FX-345.
 
FREQ stock dropped almost 10% today. What does that mean?
It could be that an investor found something else more potentially profitable in the short term, and wanted to make money faster, or an early investor needed some money quickly, or they got bored of waiting. No idea really, but it's the beginning of February, and I doubt that insiders would have knowledge a month or two ahead of the supposed press release.
 
FREQ stock dropped almost 10% today. What does that mean?
It means the stock went down 10% today; it's the nature of small market cap, no revenue generating biotech.
It could be that an investor found something else more potentially profitable in the short term, and wanted to make money faster, or an early investor needed some money quickly, or they got bored of waiting. No idea really, but it's the beginning of February, and I doubt that insiders would have knowledge a month or two ahead of the supposed press release.
The study's primary completion date was on December 30th, so I'm sure they've unblinded sometime in the last month so there are probably a select few at FREQ that already know that results.
 
FREQ stock dropped almost 10% today. What does that mean?
Probably just people taking some profits. The stock would have crashed back to $1.00 if the news leaked about the results coming out Q1 of this year. Only 425,000 shares traded today. It will go back to $1.00 or less if the FX-322 trial results coming out are bad and insiders knew about it. Maybe @Chad Lawton would like to elaborate more.
 
From Seinfeld "The Stock Tip" episode:

VANESSA: I said, the market fluctuates. Remember?

JERRY: Look, Vanessa, of course the market fluctuates. Everybody knows that. I just got fluctuated out of four thousand dollars!
 
Probably just people taking some profits. The stock would have crashed back to $1.00 if the news leaked about the results coming out Q1 of this year. Only 425,000 shares traded today. It will go back to $1.00 or less if the FX-322 trial results coming out are bad and insiders knew about it. Maybe @Chad Lawton would like to elaborate more.
There really isn't much to elaborate on. The stock has had dozens and dozens of 10% up and down days over the last 2 years for no reason at all. The stock ran up over 100% in a month and people are reading into a 10% drop.
 
With regards the FREQ stock, the thing to look out for is a consistent drop, and some sharp drops over the coming weeks. Look at what happened to OTIC in July prior to them releasing results on 1st August 2022.
 
As an aside, Michelle Solly, a biotech analyst on Twitter, did a really good write-up on Frequency Therapeutics 2 years ago, right before the Phase 2a results. Her analysis is on the original Phase 1/2 trial, but she brought up a lot of points that weren't actively being discussed at the time. Sometimes we get ourselves into a bubble and form echo chambers. It's good to get some analysis from people outside of those bubbles.

I haven't seen any good analysis of the later trials, but I hope people are tempering their expectations.
 
As an aside, Michelle Solly, a biotech analyst on Twitter, did a really good write-up on Frequency Therapeutics 2 years ago, right before the Phase 2a results. Her analysis is on the original Phase 1/2 trial, but she brought up a lot of points that weren't actively being discussed at the time. Sometimes we get ourselves into a bubble and form echo chambers. It's good to get some analysis from people outside of those bubbles.

I haven't seen any good analysis of the later trials, but I hope people are tempering their expectations.
I just hope they can reach their goals with FX-322. I'm wondering why they didn't go straight with FX-345 with its probably better delivery profile. Even if it's not applicable for my kind of hearing loss and tinnitus, it would really give them time and money for further optimisation. It's really a thrill.
 
I'm wondering why they didn't go straight with FX-345 with its probably better delivery profile. Even if it's not applicable for my kind of hearing loss and tinnitus, it would really give them time and money for further optimisation. It's really a thrill.
Could be a number of things. Cost of production, not having the adequate amount of research to risk jumping into that variant, or the design simply wasn't finished when FX-322 started clinical research.
 
There really isn't much to elaborate on. The stock has had dozens and dozens of 10% up and down days over the last 2 years for no reason at all. The stock ran up over 100% in a month and people are reading into a 10% drop.
FREQ is downturning. Down almost everyday for a week in a row, but not crazy volume. An insider recently bought 105,000 shares though. Hope this doesn't dictate their upcoming trial results. I would think we would see a lot more volume.

Chad Lawton, are you holding this long term? Or are you selling some off on the spikes like we had in mid January?
 
FREQ is downturning. Down almost everyday for a week in a row, but not crazy volume. An insider recently bought 105,000 shares though. Hope this doesn't dictate their upcoming trial results. I would think we would see a lot more volume.

Chad Lawton, are you holding this long term? Or are you selling some off on the spikes like we had in mid January?
I'm holding long term, I pay no attention to the short term price fluctuations. No insider has bought any shares in the last year and a half.
 
I have not posted in this thread for almost 4 years. I gotta say that it exceeded my expectations with the word recognition scores. I hope they would have tested audiogram with higher frequencies since FX-322 is supposed to target those. I hope we would hear the results soon and get promising results to continue with FX-345 :)

Cheers!
 
I think it is a pity, that even with little improvements, these companies may not be able to launch their products into the market. I think of Otonomy.

There is a lot of knowledge within these companies, scientists and research. Even if something provides only a small amount of improvement, it should be considered to put into the market. Many of us would be pleased for that.

I hope Frequency Therapeutics can continue to get funding and keep pushing on their research.
 
I think it is a pity, that even with little improvements, these companies may not be able to launch their products into the market.
The FDA is specific on approving a drug to be sold in the US:

1. Favorable safety profile (low risk, or well-defined risks).
2. Specific target conditions the drug intends to treat.
3. Specific patient population that can see reliable benefits.

IMO:

Frequency Therapeutics has made the case to satisfy 1 and 2 through existing trial data. 3 is outlined in their recruiting practices for the Phase 2b.

If 3 is satisfied by the next data release. It seems reasonable the FDA would either approve a third Phase or expedited approval.
 
The FDA is specific on approving a drug to be sold in the US:

1. Favorable safety profile (low risk, or well-defined risks).
2. Specific target conditions the drug intends to treat.
3. Specific patient population that can see reliable benefits.

IMO:

Frequency Therapeutics has made the case to satisfy 1 and 2 through existing trial data. 3 is outlined in their recruiting practices for the Phase 2b.

If 3 is satisfied by the next data release. It seems reasonable the FDA would either approve a third Phase or expedited approval.
I hope so @Diesel. Even if the effects are not that big, but just moderate/slight improvements, if the treatment is safe, I think it should be approved.

It would be a pity for Frequency Therapeutics to shut down. Another company with tons of knowledge and research gone.
 

Log in or register to get the full forum benefits!

Register

Register on Tinnitus Talk for free!

Register Now